MedTrace Logo

Cycloplegic Refraction in Pediatric Patients With Esotropia

NCT06077682 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-10-11

No results posted yet for this study

Summary

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations with esotropia. This will be a prospective double-blinded randomized clinical trial (RCT), multi-center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.

Conditions

  • Cycloplegia
  • Refractive Errors
  • Esotropia
  • Vision Disorders

Interventions

DRUG

Cyclopentolate

Well-known eye drop used for cycloplegic refraction among children.

DRUG

Tropicamide

Well-known eye drop used for cycloplegic refraction among children.

Sponsors & Collaborators

  • Jordan University of Science and Technology

    collaborator OTHER

  • Yarmouk University

    collaborator OTHER

  • Islamic Hospital, Jordan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
3 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-09-01
Completion
2024-12-01

Countries

  • Jordan
  • Qatar

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06077682 on ClinicalTrials.gov